Related Experiment Videos
Prevention of chronic lung disease in preterm infants by early postnatal dexamethasone therapy
1Department of Pediatrics, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Insights
Early dexamethasone therapy may reduce chronic lung disease (CLD) in preterm infants with respiratory distress syndrome (RDS). Further large trials are needed to confirm these promising findings for neonatal care.
Area of Science:
- Neonatology
- Pediatric Pulmonology
- Pharmacology
Background:
- Respiratory distress syndrome (RDS) is a common condition in preterm infants.
- Chronic lung disease (CLD) is a significant complication of RDS.
- Pulmonary inflammation is a key factor in the development of CLD.
Purpose of the Study:
- To investigate the efficacy of early (<12 hr) postnatal dexamethasone therapy in reducing CLD incidence.
- To assess the impact of dexamethasone on mechanical ventilation duration and extubation rates.
- To evaluate the safety profile of early dexamethasone administration.
Main Methods:
- A randomized, double-blind, controlled trial involving 40 preterm infants (500-1,999 gm) with severe RDS.
- Infants received mechanical ventilation within 6 hours of birth.
- Dexamethasone (0.5 mg/kg/d for 1 week, then tapered) or saline placebo was administered.
Main Results:
- Early dexamethasone therapy showed a trend towards reducing CLD incidence by Day 28.
- Survivors in the dexamethasone group had higher extubation rates.
- Transient hyperglycemia and hypertension were observed in the treated group, with no significant differences in mortality, sepsis, or intraventricular hemorrhage.
Conclusions:
- Early postnatal dexamethasone therapy may be effective in lessening CLD in preterm infants.
- Further large-scale randomized controlled trials are warranted to substantiate these findings.
- Dexamethasone offers a potential therapeutic strategy for preventing CLD in high-risk neonates.
Abstract:
Recent studies suggest that early dexamethasone therapy may lessen the pulmonary inflammation in preterm infants with respiratory distress syndrome (RDS). To investigate whether early (<12 hr) postnatal dexamethasone therapy would reduce the incidence of chronic lung disease (CLD), a randomized, double-blind, controlled trial was conducted in 40 infants (birth weights from 500 to 1,999 gm) who had severe RDS and required mechanical ventilation within 6 hr of birth. All infants received one dose of Survanta before they were randomly assigned to control (saline placebo) or dexamethasone-treated groups (0.5 mg/kg/d for 1 week, then tapered over 3 weeks). Sequential analysis was performed with the end point of assessment being the presence or absence of CLD on postnatal Day 28. Statistical significance favoring dexamethasone was reached when 12 consecutive pairs in which one infant had CLD and the other did not have CLD showed that ten pairs favored dexamethasone and two pairs favored control treatment. Among the survivors, 12/15 were extubated in the dexamethasone group and 9/16 in the control group at the end of study. Infants in the treated group had transient hyperglycemia and hypertension. There was no difference between the groups in mortality and in incidence of sepsis or intraventricular hemorrhage. We conclude that early postnatal dexamethasone therapy is potentially effective in the lessening of CLD in preterm infants. To substantiate our result, large randomized controlled trials are needed and warranted.